Abstract: A process for enhancing the filterability of organic pigments, which comprises adding to an aqueous pigment suspension 0.5 to 15% by weight, based on the pigment, of an unbranched aliphatic 1,2-dihydroxy compound containing 8 to 22 carbon atoms, and stirring the mixture for at least 15 minutes in the temperature range from 20.degree. to 100.degree. C.Pigments treated by the process of this invention have substantially enhanced filterability as compared with identical pigments which have not been treated with the 1,2-dihydroxy compound.

Abstract: Curable mixtures containing(a) an aromatic bismaleimide of formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different and each is C.sub.1 -C.sub.4 alkyl, and R.sub.3 and R.sub.4 are each independently of the other a hydrogen or halogen atom, and (a) a propenyl compound of formula II ##STR2## wherein m and n are each independently of the other 1 or 2, Z is a hydrogen atom or C.sub.1 -C.sub.4 alkoxy, and A is a radical of formula IIa, IIb or IIc ##STR3## wherein D is --SO.sub.2 -- or --CO-- or is a radical of formula ##STR4## wherein X and X.sub.1 are each independently of the other --CO--, --SO.sub.2 -- or --O--, and p is 0 or 1, E is phenylene or a radical of formula V ##STR5## wherein G is ##STR6## and q is 0 or 1, are readily processable, well suited for the preparation of prepregs or fibre-reinforced composites, and give mouldings having excellent fracture toughness.

Abstract: The invention relates to novel processes and intermediates for the preparation of 5-amino-4-hydroxyvaleric acid derivatives of the formula ##STR1## in which R.sup.1 represents hydrogen, optionally substituted alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl, aryl-lower alkyl or the radical of a natural amino acid, R.sup.2 represents hydrogen, optionally substituted alkyl, cycloalkyl, cycloalkyl-lower alkyl, aryl, aryl-lower alkyl, amino, hydroxy, mercapto, sulphinyl, sulphonyl or the radical of a natural amino acid, and R.sup.3 represents optionally substituted hydroxy or amino, by sigmatropic rearrangement of a suitable allyl ester, halolactonization of the resulting .gamma.,.delta.-unsaturated acid or of a suitable derivative thereof, exchange of halogen for a nitrogen-containing nucleophile, opening of the lactone ring and freeing of the amino group. Compounds of the formula I are starting materials for the preparation of renin-inhibitors which have an anti-hypertensive action.

Abstract: Novel compositions are described which comprise an elastomer or a lubricant and at least one compound of the formulae I or II ##STR1## The symbols R.sub.1, R.sub.2, R.sub.3, Z.sub.1 and Z.sub.2 are as defined in claim 1.The compounds of the formula II and some of the compounds of the formula I are novel, and they are used especially as antioxidants.

Abstract: An epoxy resin composition comprising an epoxy resin which is solid at room temperature and contains on average more than epoxy group per molecule, and a quaternary pyrrolidinium salt as advancement catalyst.When advanced with compounds containing two phenolic hydroxyl groups, these compositions give excellent products of low viscosity which are suitable, for example, for use in powder resin coating.

Abstract: The compounds of the formula ##STR1## in which one of the groups R.sup.1, R.sup.2 and R.sup.3 represents hydrogen, C.sub.1-8 -alkyl, C.sub.3-6 -cycloalkyl, phenyl optionally substituted by halogeno, C.sub. 1-4 -alkyl, C.sub. -4 -alkoxy and/or trifluoromethyl, or C.sub.7-10 -phenylalkyl optionally substituted in the phenyl moiety by halogeno, C.sub.1-4 -alkyl C.sub.1-4 -alkoxy and/or trifluormethyl, and the other two are hydrogen, or salts thereof.These compounds have valuable pharmaceutical properties.

Abstract: A synthetic resin based on a polystyrene that can be used as a support for solid phase peptide synthesis and that has been cross-linked with from 0 to 5 mol % of divinyl benzene, characterized in that it has been substituted at benzene rings of its skeletal structure by groups of the formula ##STR1## in which X represents --O-- or --NH-- and R represents C.sub.1 -C.sub.4 -alkyl, as a support renders possible the solid phase synthesis of peptides and peptide amides that are, if desired, protected at the N-terminal and/or at other functional groups. The resin is manufactured by reaction of a customary chloromethylated polystyrene resin with an alkali metal salt of the corresponding 4-hydroxybenzophenone and subsequent reduction of the carbonyl group and, optionally, amination.

Abstract: The invention relates to novel substituted azacyclohexyl derivatives of formula ##STR1## and salts of thereof in which the structural elements --A.sub.1 -A.sub.2, --A.sub.3 -A.sub.4 -- and --A.sub.5 -A.sub.6 -- are each ethylene or vinylene or the elements --A.sub.1 -A.sub.2 -- and --A.sub.3 -A.sub.4 -- are each ethylene and --A.sub.5 -A.sub.6 -- is vinylene, X is >CR.sub.6 -- or >N-- and R.sub.6 is alkyl or hydrogen, alk is an aliphatic hydrocarbon radical or a bond, R.sub.1 is hydrogen or acyl, R.sub.2 is hydrogen or acetyl, R.sub.3 and R.sub.4 together are a bond or each is hydrogen, R.sub.5 is hydrogen, a cycloaliphatic hydrocarbon radical, aryl or heteroaryl and R.sub.7 is hydrogen or alkyl, with the proviso that when --A.sub.1 -A.sub.2 --, --A.sub.3 -A.sub.4 -- and --A.sub.5 -A.sub.6 -- are each vinylene, X is >N--, R.sub.1 is hydrogen or trialkylacetyl, R.sub.2 is hydrogen or acetyl, R.sub.3 and R.sub.4 together are a bond and alk is methylene, R.sub.

Abstract: The invention relates to solid drug formulations obtainable by lyophilization for the preparation of stable suspensions and to the stable suspensions themselves, which formulations contain 4-hydroxy- or 4-acyloxy-4-androstene-3,17-diones.

Abstract: The invention describes a process for culturing proliferating aggregates of plant cells, which comprises (a) uniformly plating isolated protoplasts, or isolated cells regenerated from protoplasts, in or on an agarose-solidified culture medium, and/or (b) cutting this pretreated and solidified culture medium into segments, transferring said segments to a liquid nutrient solution and continuing culturing in both cases until the cell aggregates have attained the desired size.

Abstract: There are disclosed novel pharmaceutical compositions which comprise diclofenac or a salt thereof, a penetration agent such as 1-n-dodecylazacycloheptan-2-one or dimethyllauroylamide and, as vehicle, a mineral oil. These compositions have excellent skin penetration properties and can therefore be used in transdermal therapeutic systems (TTS) as drug reservoir.

Abstract: The novel compounds of the formula (I) ##STR1## in which R.sub.1 is di(C.sub.1 -C.sub.4 -alkyl)amino, C.sub.1 -C.sub.4 -alkoxy, a 5-membered to 7-membered nitrogen containing heterocyclic group with the nitrogen atom bonded to the triazine ring, or a group of the formula (II), ##STR2## R.sub.2 and R.sub.4 which are identical or different are C.sub.1 -C.sub.12 -alkyl, C.sub.5 -C.sub.7 -cycloalkyl, benzyl or 1,2,2,6,6-pentamethyl-4-piperidyl, n is 2 or 3 and, if n is 2, R.sub.3 is a group ##STR3## with R.sub.5 and R.sub.7, which are identical or different, being hydrogen, C.sub.1 -C.sub.12 -alkyl, C.sub.5 -C.sub.7 -cycloalkyl, benzyl or 1,2,2,6,6-pentamethyl-4-piperidyl and R.sub.6 being C.sub.2 -C.sub.12 -alkylene, cyclohexylene, cyclohexylenedimethylene or methylenedicyclohexylene, or R.sub.3 is the divalent radical of a 6-membered to 7-membered heterocyclic compound with two nitrogen atoms which are each bonded to a triazine ring, or, if n is 3, R.sub.3 is a group ##STR4## with R.sub.8 and R.sub.

Abstract: Imidazoline compounds of formula ##STR1## where n denotes 2 or 3, is suitable as cure accelerator in curable epoxide resin compositions comprising a latent curing agent.

Abstract: A method of inhibiting the deposition of paraffin wax, asphaltene, or mixtures thereof in a crude oil contaminated with paraffin wax, asphaltene, or mixtures thereof and susceptible to such depositions comprising the step of incorporating into said crude oil an effective deposition inhibiting amount of an oil soluble organic compound having at least one oleophobic and hydrophobic fluoroaliphatic group, and antideposition stabilized crude oil compositions containing said compound, are disclosed.

Abstract: Compounds of the formulae I and II ##STR1## in which A is a radical of the formulae III, IV or V ##STR2## R.sub.1 and R.sub.4 are --H or --Cl, R.sub.2 and R.sub.5 are --H, halogen, --NO.sub.2, --CN, C.sub.1 -C.sub.4 -alkyl, C.sub.1 -C.sub.4 alkoxy, --CF.sub.3 or phenyloxy which is unsubstituted or substituted by one or two chlorine atoms and/or one or two methyl or methoxy groups, and R.sub.3 is alkyl having at least 10 C atoms, X is a radical of the formulae --NH--, --O--, ##STR3## n is the number 1 or 2, Y is the radical of the formulae --COO--, --OOC--, --CONH-- or --NHCO-- or a radical of the formulae ##STR4## in which R.sub.1 and R.sub.2 are as defined above, D is an aromatic heterocyclic 5- or 6-membered ring, in which the ring contains 1 or 2 N atoms and may additionally contain an O atom or S atom, Z is --H, --Br, --OCH.sub.3, --CN or --NO.sub.2 and X.sub.1 and X.sub.2, independently of one another, are --H, halogen, --CH.sub.3, --OCH.sub.3, --OC.sub.2 H.sub.5 or --NO.sub.2 and X.sub.

Abstract: The invention relates to a covered, solid retard form which in the case of oral administration remains in the stomach during periodic emptying and ensures continuous release. This dosage form contains the following components:(a) at least one component that expands on contact with body fluid and that contains a physiologically active substance or a combination of such substances,(b) at least one permeable hydrophilic membrane which surrounds component (a) and which is expansible at the site of use, and optionally(c) a covering which surrounds components (a) and membrance (b) and which disintegrates without delay under the action of a body fluid at the site of use.

Abstract: The present invention relates to a method for the treatment of renal cell carcinoma comprising administering to a warm blooded mammal in need thereof a therapeutically effective amount of N-acetylmuramyl-L-alanyl-D-isogutamin-yl-L-alanine-2-(1,2-dipalmitoyl-sn-g lyc ro-3-hydroxyphosphoryloxy)ethylamide monosodium salt preferably encapsulated in a multilamellar liposomal composition comprising phosphatidylcholine and phosphatidylserine.

Abstract: The present invention relates to a negative photoresist essentially comprising(a) at least one solid, film-folrming polyphenol,(b) at least one polyfunctional epoxy resin and/or one polyfunctional vinyl ether compound, each of which can be dissolved, in the uncured state, in aqueous alkaline media with salt formation,(c) at least one cationic photoinitiator for component (b) and(d) customary additives, if desired.Components (a) and (b) can also be combined in one molecule. The resist can be developed in aqueous alkaline media.

Abstract: The present invention relates to a therapeutic system with systemic action for peroral administration, having a compartment for active ingredients, which system contains in that compartment sparingly soluble active ingredients, swelling agents and, optionally, water-soluble substances for producing an osmotic pressure.

Abstract: The present invention relates to amides of formula I ##STR1## wherein R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen or methyl, m is 1 to 5 and n is 1 to 5 and R.sup.4 is --NH.sub.2 or is derived from a mono- to pentavalent amine.Intermediates of formula VIII ##STR2## wherein R.sup.1, R.sup.2, R.sup.3 and m are as defined above and X is a carboxylic acid or acid ester group, --COCl, --COBr, --CHO or --CN, are also described.The compounds of formula I can be polymerized thermally. They are suitable for the preparation of adhesives, matrix resins or electrical insulating materials.